Wave Life Sciences (NASDAQ:WVE) Upgraded to Outperform at Leerink Partnrs

Leerink Partnrs upgraded shares of Wave Life Sciences (NASDAQ:WVE – Free Report) from a market perform rating to an outperform rating in a report released on Tuesday, PriceTargets.com reports. Leerink Partnrs also issued estimates for Wave Life Sciences’ Q4 2023 earnings at $0.02 EPS, FY2023 earnings at ($0.36) EPS, Q1 2024 earnings at ($0.16) EPS, […]

Leave a Reply

Your email address will not be published.

Previous post Stifel Nicolaus Raises Tecnoglass (NASDAQ:TGLS) Price Target to $48.00
Next post Germany equates Russia to Seychelles